Chimerix, Inc. (CMRX)

NASDAQ: CMRX · IEX Real-Time Price · USD
1.190
+0.010 (0.85%)
Feb 26, 2024, 4:00 PM EST - Market closed
0.85%
Market Cap 104.89M
Revenue (ttm) 1.13M
Net Income (ttm) -84.89M
Shares Out 88.89M
EPS (ttm) -0.95
PE Ratio n/a
Forward PE 1.21
Dividend n/a
Ex-Dividend Date n/a
Volume 7,086
Open 1.190
Previous Close 1.180
Day's Range 1.170 - 1.210
52-Week Range 0.880 - 1.770
Beta 1.10
Analysts Strong Buy
Price Target 8.00 (+572.27%)
Earnings Date Feb 29, 2024

About CMRX

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 2 clinical trial for treating tumors, which harbor the H3 K27M mutation in glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imiprid... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 11, 2013
Employees 89
Stock Exchange NASDAQ
Ticker Symbol CMRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for CMRX stock is "Strong Buy." The 12-month stock price forecast is $8.0, which is an increase of 572.27% from the latest price.

Price Target
$8.0
(572.27% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024

DURHAM, N.C., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients fac...

5 days ago - GlobeNewsWire

Chimerix Appoints Lisa Decker to Board of Directors

Seasoned Industry Executive Brings More Than 25 Years of Leadership and Business Development Experience Seasoned Industry Executive Brings More Than 25 Years of Leadership and Business Development Exp...

2 months ago - GlobeNewsWire

Chimerix Promotes Michelle LaSpaluto to Chief Financial Officer

DURHAM, N.C., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients fac...

3 months ago - GlobeNewsWire

Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DURHAM, N.C., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on November 20, 2023, the Compensation Committee of Chimerix's Board of Directors granted an inducement awa...

3 months ago - GlobeNewsWire

Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer

Seasoned Executive Brings More Than 25 Years of Industry Leadership Experience in Oncology Commercialization and Corporate Business Development Seasoned Executive Brings More Than 25 Years of Industry...

3 months ago - GlobeNewsWire

Chimerix Reports Third Quarter 2023 Financial Results and Provides Operational Update

– Phase 3 ACTION Study Ongoing with 113 Sites Activated Across 12 Countries; Interim Survival and PFS Data on Track to Report in 2025 –

4 months ago - GlobeNewsWire

Chimerix to Report Third Quarter 2023 Financial Results and Provide an Operational Update on November 2, 2023

DURHAM, N.C., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients fac...

4 months ago - GlobeNewsWire

Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to ONC201 Treatment of H3 K27M-Mutant Diffuse Midline Gliomas Published in "Cancer Discovery"

Patients Treated with ONC201 Demonstrated Median Overall Survival (mOS) of 21.7 Months in the Front-Line Setting, Post Radiation, Versus 12 Months mOS Historical Control

6 months ago - GlobeNewsWire

Chimerix Reports Second Quarter 2023 Financial Results and Provides Operational Update

– Phase 3 ACTION Study Ongoing with 77 Sites Activated Across 11 Countries; Reiterate First Interim Overall Survival Analysis Expected Early 2025 –

7 months ago - GlobeNewsWire

Chimerix to Report Second Quarter 2023 Financial Results and Provide an Operational Update on August 3, 2023

DURHAM, N.C., July 27, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients fac...

7 months ago - GlobeNewsWire

Chimerix Announces Promotion of Michael T. Andriole to President and Chief Executive Officer

Mike Sherman to Transition to Chair of the Board of Directors Martha Demski to Assume Role of Lead Independent Director DURHAM, N.C., June 27, 2023 (GLOBE NEWSWIRE) -- Chimerix, Inc. (NASDAQ:CMRX), a ...

8 months ago - GlobeNewsWire

Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference

DURHAM, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients faci...

9 months ago - GlobeNewsWire

Chimerix to Participate in Cancer Moonshot Brain Cancers Forum on Glioblastoma (GBM) and Diffuse Intrinsic Pontine Glioma (DIPG) at White House

DURHAM, N.C., May 25, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients faci...

9 months ago - GlobeNewsWire

Chimerix Reports First Quarter 2023 Financial Results and Provides Operational Update

– European Union Study Authorization for Phase 3 ACTION Received, Reiterate First Efficacy Data Expected Early 2025 –

10 months ago - GlobeNewsWire

Chimerix to Report First Quarter 2023 Financial Results and Provide an Operational Update on May 4, 2023

DURHAM, N.C., April 27, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients fa...

10 months ago - GlobeNewsWire

Chimerix Announces Presentation of Multiple Imipridone Datasets at American Association for Cancer Research Annual Meeting

Key Presentation Highlights Ability of ONC201 to Reverse Epigenetic Signature of H3 K27M Mutation in Glioma Patients

11 months ago - GlobeNewsWire

Chimerix Reports Fourth Quarter and Year End 2022 Financial Results and Provides Operational Update

- Continued Execution and Progress Towards Commercial Approval of Dordaviprone (ONC201) with Global Launch of Phase 3 ACTION Study –

1 year ago - GlobeNewsWire

Chimerix to Present at 41st Annual J.P. Morgan Healthcare Conference

DURHAM, N.C., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients fac...

1 year ago - GlobeNewsWire

Chimerix Announces Successful Launch of ONC201 Phase 3 ACTION Study at Society for Neuro-Oncology Conference and Provides Operational Update

– Natural Disease History study indicates median overall survival in recurrent H3 K27M-mutant diffuse glioma of 5.1 months compared to 13.7 months in the prior ONC201 Phase 2 efficacy analysis –

1 year ago - GlobeNewsWire

Chimerix Responds to Rubric Capital Management

Highlights Confidence in Ongoing Strategy and Future Clinical Development Plans Highlights Confidence in Ongoing Strategy and Future Clinical Development Plans

1 year ago - GlobeNewsWire

Rubric Capital Management Sends Letter to Chimerix Board of Directors

NEW YORK--(BUSINESS WIRE)--Rubric Capital Management LP (“Rubric”), an investment adviser whose managed funds and accounts collectively own approximately 8.5% of the common stock of Chimerix, Inc. (“C...

1 year ago - Business Wire

Chimerix Reports Third Quarter 2022 Financial Results and Provides Operational Update

– ONC201 Phase 3 ACTION Study On-Track to Open Enrollment in November –

1 year ago - GlobeNewsWire

Chimerix to Report Third Quarter 2022 Financial Results and Provide an Operational Update on November 3, 2022

DURHAM, N.C., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend lives of patients facing ...

1 year ago - GlobeNewsWire

Chimerix Announces Closing of TEMBEXA Sale to Emergent BioSolutions

- $238 Million in Upfront Payment Received at Closing with Additional $136.5 Million in Potential Milestone Payments Plus Royalties -

1 year ago - GlobeNewsWire

Chimerix to Present at H.C. Wainwright 24th Annual Global Investment Conference

DURHAM, N.C., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients...

1 year ago - GlobeNewsWire